In conclusion, our meta-analysis indicated that XPD Lys751Gln polymorphism may be useful prognostic factors for assessing objective response and progression risk in advanced NSCLC patients treated with platinum-based regimen according to different ethnicities. This evidence concerns the gene ERCC2 and non-small cell lung carcinoma.